Chimerix Investor Conference Presentation Deck slide image

Chimerix Investor Conference Presentation Deck

Patient Demographics and Disease Characteristics Age (years), median (range) <18 years, N(%) 18 - <40 years, N(%) >40 years, N(%) Gender, N(%) Male Female Race, N(%) White Other Black Asian Not reported Body weight (kg), median (range) Performance status (KPS/LPS), N(%) 60-70 80 90-100 10 N=50 30 (870) 4 (8%) 32 (64%) 14 (28%) 27 (54%) 23 (46%) 39 (78%) 6 (12%) 3 (6%) 1 (2%) 1 (2%) 88 (29 - 199) 14 (28%) 20 (40%) 16 (32%) ¹Multifocal disease includes non-target lesions ²Sum of product of diameters of enhancing target lesions per BICR Primary tumor location, N(%) Thalamic Other midline Multifocal disease¹, N(%) >1 Target lesion, N(%) Tumor size² (cm2), median (range) H3 K27M detection method IHC, N(%) NGS, N(%) First recurrence, N(%) Prior temozolomide, N(%) Time from recurrence, days, median (range) Time from prior radiation, months, median (range) Time from initial diagnosis, months, median (range) Daily steroid dose (mg, dex equiv): median (range) N=50 33 (66%) 17 (34%) 23 (46%) 9 (18%) 10.4 (1.640.8) 47 (94%) 3 (6%) 37 (74%) 44 (88%) 20 (1 126) 7.5 (3104) 10.9 (5-105) 1.1 (0.0 12.0)
View entire presentation